Cogent Biosciences, Inc. COGT revenue by segment, product and geography
Cogent Biosciences, Inc.'s fiscal year ending 2025-12-31 carries a reported breakdown by business segments.
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Latestage Development$120M36.0%-0.7% yoy
- Research And Development Personnel Related$64M19.2%+36.1% yoy
- Stock-Based Compensation Expense$46.1M13.8%+16.0% yoy
- Other Operational Infrastructure And Advisory Support$40.4M12.1%+50.4% yoy
- Early Stage Preclinical And Discovery Programs$40.1M12.0%+42.5% yoy
- Research And Development Software Facilities And Other Strategic Support$20.1M6.0%+85.8% yoy
- +1 more member in the filing
Members sum to $333M against -$333M consolidated (residual -$667M) - eliminations or corporate lines the filer did not tag on this axis.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.